Oral JAK Inhibitor Promising in Ankylosing Spondylitis

Given that “no radiographic progression was observed in approximately 80% of patients who received secukinumab over 104 weeks, data suggest that there may be a lower rate of structural progression with secukinumab, compared with earlier intervention studies, although this remains to be proven,” he added.

“From my perspective, these data justify further investigation of JAK inhibitors in ankylosing spondylitis in larger phase 3 trials,” said Denis Poddubnyy, MD, from Charité Universitätsmedizin in Berlin.

“We see the effect of tofacitinib in the primary end-point analysis, in the observed data, and in the MRI data,” he told Medscape Medical News in an email.

“This is a strong signal, and suggests that JAK blockade might be effective in ankylosing spondylitis at least on the same level as currently approved biologics, including tumor necrosis factor and interleukin-17 blockers,” he added.

Be the first to comment

Leave a Reply

Your email address will not be published.